Vilin Bio Med opened higher at ₹54.50, compared with its previous close of ₹52.05. During today's session, the stock has traded between ₹54.50 and ₹54.50, with an average traded price of ₹54.50. It is currently showing an upward intraday trend.
An investment of ₹10,000 made 4 years ago in Vilin Bio Med is now worth
₹ 19,123.00
giving a profit of
₹ 9,123.00 (91.23%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
+2.45 (+4.71%)
Day High
₹54.50
Day Low
₹54.50
Day Open
₹54.50
Prev Close
₹52.05
Volume
4,000
Value Traded
₹0.02 Cr
1W Return
1.40%
1M Return
-7.63%
3M Return
18.48%
6M Return
37.02%
1Y Return
113.73%
Market Cap (₹ Cr.)
83
PE Ratio
41.30
PB Ratio
2.80
Dividend Yield
-
ROE
6.80%
ROCE
10.21%
Book Value (₹)
18.60
Face Value (₹)
10.00
EPS (TTM)
-
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
1.40%
6 Week
-
1 Month
-7.63%
3 Month
18.48%
9 Month
96.04%
No data available.
Vilin Bio Med appoints Ms. Neha Lahoti as Company Secretary
Vilin Bio Med Limited announced the appointment of Ms. Neha Lahoti as Company Secretary and Compliance Officer effective June 27, 2026. This follows the resignation of Ms. Anjali Choudhary from the same roles due to personal reasons. The Board approved the changes during a meeting held on June 27, 2026.
3mo agoVilin Bio Med FY26 net profit surges 763% to ₹192.88 lakh
Vilin Bio Med reported a 763% increase in net profit to ₹192.88 lakh for FY26, with revenue from operations rising 185% to ₹4,226.30 lakh. The Board approved the audited results, and statutory auditors issued an unmodified opinion. The company raised ₹338.00 lakh via a preferential allotment and confirmed no deviation in fund utilisation.
3mo agoVilin Bio Med confirms no promoter encumbrance in FY26
Vilin Bio Med confirmed in an NSE filing that promoters and PACs held no encumbrances on shares in FY26. The disclosure under SEBI regulations lists 90,04,374 shares held by promoters and promoter group members.
3mo agoVilin Bio Med accepts resignation of CFO Avula Hariprasad
Vilin Bio Med accepted the resignation of Avula Hariprasad as Chief Financial Officer effective June 11, 2026. Hariprasad stepped down due to pre-occupation and other engagements. The company disclosed the change pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015.
4mo agoVilin Bio Med reclassifies outgoing promoter to public
Vilin Bio Med Limited reclassified outgoing promoter Mr. Devireddy Srinivas Reddy to the public category after an open offer concluded on September 15, 2025. Reddy holds 4,45,425 equity shares, representing 3.19% of the total voting capital. The move complies with SEBI LODR Regulation 31A(10).
4mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,770.70 | +0.61% | ₹4,24,850.24 | 34.83 | +5.97% | |
| ₹9,285.00 | -1.50% | ₹2,46,487.58 | 85.12 | +43.41% | |
| ₹4,642.90 | -0.84% | ₹1,76,600.99 | 82.55 | +31.42% | |
| ₹1,132.50 | -0.17% | ₹1,12,967.31 | 24.74 | +14.00% | |
| ₹2,059.40 | -0.47% | ₹1,11,271.90 | 102.63 | +134.89% | |
| ₹1,329.60 | +1.40% | ₹1,07,412.86 | 31.62 | -14.87% | |
| ₹1,240.00 | +0.86% | ₹1,03,500.36 | 32.26 | -1.93% | |
| ₹2,372.00 | -1.17% | ₹97,974.30 | 47.92 | -3.57% | |
| ₹1,684.60 | -1.31% | ₹96,928.16 | 26.40 | +49.04% | |
| ₹1,953.60 | +0.96% | ₹89,336.17 | 16.03 | -0.29% | |
| ₹2,265.30 | -0.78% | ₹63,932.35 | 35.82 | +16.81% | |
| ₹5,250.00 | +0.86% | ₹62,771.63 | 28.34 | -3.75% |
An investment of ₹10,000 made 4 years ago in Vilin Bio Med is now worth
₹ 19,123.00
giving a profit of
₹ 9,123.00 (91.23%)
Note: Past profits do not guarantee future returns.
